ECCO Medical to Participate in Global Clinical Trial for Treating Hypervascular Tumors

By News Release

ECCO Medical, an endovascular treatment center in Colorado, and co-founder Charles Nutting, DO, FSIR, announced their participation in the Embrace Hydrogel Embolic System (HES) global randomized clinical trial for the treatment of hypervascular tumors. Sponsored by Instylla, Inc., the study focuses on developing next-generation liquid embolics for interventional radiology. Instylla completed a successful First-in-Human (FIH) study and Embrace HES was found to be effective at embolizing malignant and benign hypervascular tumors.

ECCO Medical was selected as a clinical trial site because of its doctors' reputation and expertise in treating patients using embolization techniques. "We are excited to be a participating center in the study and look forward to evaluating Embrace hydrogel in treating hypervascular tumors," said Dr. Charles Nutting, Board Certified Interventional Radiologist at ECCO Medical.

A hypervascular tumor, which can be found in the liver, kidney, or elsewhere, has an increased number of blood vessels, relative to other tissues. Due to the increased risk of bleeding, hypervascular tumors can be challenging to remove. Transcatheter arterial embolization (TAE) and transarterial chemoembolization (cTACE) are established treatments for hypervascular tumors, particularly for patients with limited progressive disease.

Embrace HES, an investigational product is a liquid embolic that is designed to deeply penetrate the tumor vascular bed, solidify, and stop the blood flow. The Embrace HES embolization uses no organic solvents in its formulation, does not need sizing to the vessel diameter, and eliminates the possibility of catheter entrapment. Its main components are water and polyethylene glycol (PEG). PEG has a long history of safe use in implantable medical devices.

Back To Top

ECCO Medical to Participate in Global Clinical Trial for Treating Hypervascular Tumors.  Appl Radiol. 

By News Release| June 30, 2021

About the Author

News Release

News Release

Copyright © Anderson Publishing 2022